{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:08:17Z","timestamp":1792631297016,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cll.2021.07.009","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T02:40:17Z","timestamp":1632883217000},"page":"669-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Transfusion Reactions and Adverse Events"],"prefix":"10.1016","volume":"41","author":[{"given":"Rim","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herleen","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya R.","family":"Panch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1802338","article-title":"Hemolytic transfusion reactions","volume":"381","author":"Panch","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1049909118806456","article-title":"A\u00a0retrospective chart review of transfusion practices in the palliative care unit setting","volume":"36","author":"Sirianni","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib4","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/jvim.15334","article-title":"Prevalence of naturally occurring non-AB blood type incompatibilities in cats and influence of crossmatch on transfusion outcomes","volume":"32","author":"McClosky","year":"2018","journal-title":"J\u00a0Vet Intern Med"},{"issue":"11","key":"10.1016\/j.cll.2021.07.009_bib5","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/trf.14948","article-title":"International validation of harmonized definitions for complications of blood donations","volume":"58","author":"Land","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.009_bib6","series-title":"Technical manual","author":"Hod","year":"2020"},{"key":"10.1016\/j.cll.2021.07.009_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.tcam.2018.12.005","article-title":"Transfusion medicine: an update on antigens, antibodies and serologic testing in dogs and cats","volume":"34","author":"Zaremba","year":"2019","journal-title":"Top Companion Anim Med"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/tme.12582","article-title":"International haemovigilance: what have we learned and what do we need to do next?","volume":"29","author":"Wood","year":"2019","journal-title":"Transfus Med"},{"issue":"5","key":"10.1016\/j.cll.2021.07.009_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000154811","article-title":"Hemolytic transfusion reactions","volume":"35","author":"Strobel","year":"2008","journal-title":"Transfus Med Hemother"},{"issue":"12","key":"10.1016\/j.cll.2021.07.009_bib10","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1111\/trf.16121","article-title":"Trend in ABO-incompatible RBC transfusion-related fatalities reported to the FDA, 2000-2019","volume":"60","author":"Storch","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.009_bib11","series-title":"Sentinel event policy and procedures","year":"2020"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1537-2995.1990.30790385515.x","article-title":"Reports of 355 transfusion-associated deaths - 1976 through 1985","volume":"30","author":"Sazama","year":"1990","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.009_bib13","first-page":"197","article-title":"Ordering blood for the wrong patient: getting inside the minds of ordering physicians","volume":"120","author":"Foss","year":"2005","journal-title":"Dev Biol (Basel)"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2141.2005.05702.x","article-title":"Reducing adverse events in blood transfusion","volume":"131","author":"Stainsby","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2021.07.009_bib16","series-title":"Summary data of sentinel events reviewed by the Joint commission","year":"2020"},{"key":"10.1016\/j.cll.2021.07.009_bib17","series-title":"Serious Hazards of transfusion (SHOT). Annual reports and summaries","article-title":"Summary data of sentinel events reviewed by The Joint Commission","year":"2020"},{"key":"10.1016\/j.cll.2021.07.009_bib18","series-title":"Annual SHOT report 2019","year":"2019"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/asheducation-2018.1.585","article-title":"TACO and TRALI: biology, risk factors, and prevention strategies","volume":"2018","author":"Roubinian","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib20","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.4081\/hr.2018.7724","article-title":"Transfusion-associated graft-versus-host disease: a concise review","volume":"10","author":"Manduzio","year":"2018","journal-title":"Hematol Rep"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1537-2995.2008.02050.x","article-title":"Transfusion medicine illustrated. Sudden increased incidence of transfusion reactions reported from a ward: root cause analysis","volume":"49","author":"Dubey","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tracli.2019.03.001","article-title":"Delayed hemolytic transfusion reaction in the French hemovigilance system","volume":"26","author":"Rieux","year":"2019","journal-title":"Transfus Clin Biol"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/vox.12758","article-title":"Provider trends in paediatric and adult transfusion reaction reporting","volume":"114","author":"Vossoughi","year":"2019","journal-title":"Vox Sang"},{"issue":"22","key":"10.1016\/j.cll.2021.07.009_bib24","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13137","article-title":"Wrong blood in tube - potential for serious outcomes: can it be prevented?","volume":"168","author":"Bolton-Maggs","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2021.07.009_bib26","series-title":"Transfusion medicine checklist. CAP accreditation program","year":"2017"},{"key":"10.1016\/j.cll.2021.07.009_bib27","series-title":"Standards for blood banks and transfusion services. Standards for blood banks and transfusion services","year":"2018"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1537-2995.2012.03789.x","article-title":"The immunohematologic and patient safety benefits of a centralized transfusion database","volume":"53","author":"Delaney","year":"2013","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib29","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/trf.14099","article-title":"Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions","volume":"57","author":"Cohen","year":"2017","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00062752-199911000-00012","article-title":"Pathophysiology of febrile nonhemolytic transfusion reactions","volume":"6","author":"Heddle","year":"1999","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib31","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.18632\/oncotarget.23136","article-title":"Transfusion-associated adverse reactions (TAARs) and cytokine accumulations in the stored blood components: the impact of prestorage versus poststorage leukoreduction","volume":"9","author":"Chang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cll.2021.07.009_bib32","series-title":"National healthcare safety network biovigilance component hemovigilance module surveillance protocol","year":"2018"},{"key":"10.1016\/j.cll.2021.07.009_bib33","series-title":"Technical manual","author":"Savage","year":"2017"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2006.09.001","article-title":"Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice?","volume":"21","author":"Geiger","year":"2007","journal-title":"Transfus Med Rev"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/hematology.2020000165","article-title":"The use of premedications for platelet transfusions in pediatric patients","volume":"2020","author":"McCormick","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5858\/2003-127-0316-ATR","article-title":"Allergic transfusion reactions: an evaluation of 273 consecutive reactions","volume":"127","author":"Domen","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib37","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1537-2995.1992.32692367205.x","article-title":"Severe anaphylactic reactions following transfusions of platelets to a patient with anti-Ch","volume":"32","author":"Westhoff","year":"1992","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib38","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood.V95.4.1138.004k27_1138_1143","article-title":"Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions","volume":"95","author":"Koda","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib39","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1537-2995.2007.01242.x","article-title":"Transfusion premedications: a growing practice not based on evidence","volume":"47","author":"Tobian","year":"2007","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/trf.12796","article-title":"The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based","volume":"55","author":"Sandler","year":"2015","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1537-2995.1993.33693296811.x","article-title":"Laboratory tests to exclude IgA deficiency in the investigation of suspected anti-IgA transfusion reactions","volume":"33","author":"Eckrich","year":"1993","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0887-7963(05)80026-4","article-title":"IgA anaphylactic transfusion reactions","volume":"9","author":"Sandler","year":"1995","journal-title":"Transfus Med Rev"},{"issue":"8","key":"10.1016\/j.cll.2021.07.009_bib43","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1537-2995.2010.03008.x","article-title":"Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction","volume":"51","author":"Tobian","year":"2011","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0268-960X(03)00057-2","article-title":"Optimizing platelet transfusion therapy","volume":"18","author":"Heal","year":"2004","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00062752-200111000-00013","article-title":"Single donor versus pooled random donor platelet concentrates","volume":"8","author":"Ness","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.cll.2021.07.009_bib46","doi-asserted-by":"crossref","first-page":"100593","DOI":"10.1016\/j.blre.2019.100593","article-title":"Review of current transfusion therapy and blood banking practices","volume":"38","author":"Storch","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tracli.2007.03.009","article-title":"[Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients]","volume":"14","author":"Andreu","year":"2007","journal-title":"Transfus Clin Biol"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib48","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/trf.13047","article-title":"Hypotensive transfusion reactions in the era of prestorage leukoreduction","volume":"55","author":"Pagano","year":"2015","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.cll.2021.07.009_bib49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1309\/PCARYBE0RVAFKDDK","article-title":"Acute hypotensive transfusion reactions","volume":"37","author":"Bruno","year":"2006","journal-title":"Lab Med"},{"issue":"9","key":"10.1016\/j.cll.2021.07.009_bib50","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.0041-1132.2004.04057.x","article-title":"Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage","volume":"44","author":"Arnold","year":"2004","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/ALN.0000000000000513","article-title":"Characterizing the epidemiology of perioperative transfusion-associated circulatory overload","volume":"122","author":"Clifford","year":"2015","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib52","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(19)30080-8","article-title":"Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study","volume":"6","author":"Wiersum-Osselton","year":"2019","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.cll.2021.07.009_bib53","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1111\/trf.12454","article-title":"How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention","volume":"53","author":"Andrzejewski","year":"2013","journal-title":"Transfus"},{"issue":"26","key":"10.1016\/j.cll.2021.07.009_bib54","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1056\/NEJMcp052699","article-title":"Clinical practice. Acute pulmonary edema","volume":"353","author":"Ware","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2021.07.009_bib55","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/00003246-198308000-00012","article-title":"Oxygen derived variables in acute respiratory failure","volume":"11","author":"Covelli","year":"1983","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.cll.2021.07.009_bib57","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/trf.13021","article-title":"Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions","volume":"55","author":"Roubinian","year":"2015","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib58","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood-2011-08-370932","article-title":"Transfusion-related acute lung injury: incidence and risk factors","volume":"119","author":"Toy","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bpa.2007.01.003","article-title":"TRALI--definition, mechanisms, incidence and clinical relevance","volume":"21","author":"Toy","year":"2007","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib60","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1537-2995.2012.03935.x","article-title":"The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy","volume":"53","author":"Eder","year":"2013","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.cll.2021.07.009_bib61","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1172\/JCI138136","article-title":"Complement activation on endothelium initiates antibody-mediated acute lung injury","volume":"130","author":"Cleary","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib62","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MOH.0000000000000607","article-title":"Update on the pathophysiology of transfusion-related acute lung injury","volume":"27","author":"Zeeuw van der Laan","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib63","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MOH.0000000000000462","article-title":"Delayed haemolytic and serologic transfusion reactions: pathophysiology, treatment and prevention","volume":"25","author":"Siddon","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib64","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1537-2995.2008.02014.x","article-title":"The persistence and evanescence of blood group alloantibodies in men","volume":"49","author":"Tormey","year":"2009","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.21307\/immunohematology-2019-444","article-title":"Delayed hemolytic transfusion reaction due to anti-Fyb caused by a primary immune response: a case study and a review of the literature","volume":"20","author":"Kim","year":"2004","journal-title":"Immunohematology"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1423-0410.2008.01085.x","article-title":"Delayed intravascular haemolysis following multiple asymptomatic ABO-incompatible red blood cell transfusions in a patient with hepatic failure","volume":"95","author":"Tormey","year":"2008","journal-title":"Vox Sang"},{"issue":"8","key":"10.1016\/j.cll.2021.07.009_bib67","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1537-2995.1990.30891020325.x","article-title":"The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance","volume":"30","author":"Ness","year":"1990","journal-title":"Transfusion"},{"issue":"Supplement_1","key":"10.1016\/j.cll.2021.07.009_bib68","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2019-127176","article-title":"Treatment of delayed hemolytic transfusion reactions in sickle cell disease patients by an anti-C5 antibody","volume":"134","author":"Floch","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.7326\/0003-4819-93-2-231","article-title":"Delayed hemolytic transfusion reaction presenting as sickle-cell crisis","volume":"93","author":"Diamond","year":"1980","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-3148.2012.01151.x","article-title":"What do we mean by \"Hyperhaemolysis\" and what is the cause?","volume":"22","author":"Garratty","year":"2012","journal-title":"Transfus Med"},{"issue":"12","key":"10.1016\/j.cll.2021.07.009_bib71","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/j.1537-2995.2005.00608.x","article-title":"Hyperhemolysis syndrome in anemia of chronic disease","volume":"45","author":"Darabi","year":"2005","journal-title":"Transfusion"},{"issue":"10061","key":"10.1016\/j.cll.2021.07.009_bib72","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/S0140-6736(15)01313-6","article-title":"Transfusion reactions: prevention, diagnosis, and treatment","volume":"388","author":"Delaney","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tmrv.2019.09.007","article-title":"The role of complement in post-transfusion hemolysis and hyperhemolysis reaction","volume":"33","author":"Roumenina","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"10","key":"10.1016\/j.cll.2021.07.009_bib74","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant","year":"2015","journal-title":"Transfusion"},{"issue":"5\u20136","key":"10.1016\/j.cll.2021.07.009_bib75","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin"},{"issue":"8","key":"10.1016\/j.cll.2021.07.009_bib76","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","article-title":"Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients","volume":"127","author":"Dumas","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib77","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tmrv.2020.06.002","article-title":"Hyperhemolytic transfusion reaction in non-hemoglobinopathy patients and terminal complement pathway activation: case series and review of the literature","volume":"34","author":"Cid","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib78","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1537-2995.2008.01693.x","article-title":"Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review","volume":"48","author":"Win","year":"2008","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tmrv.2009.09.006","article-title":"Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review","volume":"24","author":"Win","year":"2010","journal-title":"Transfus Med Rev"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib80","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/trf.12258","article-title":"Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion","volume":"54","author":"Uhlmann","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib81","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/trf.12876","article-title":"Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab","volume":"55","author":"Gupta","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib82","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/trf.15562","article-title":"Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab","volume":"60","author":"Lee","year":"2020","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib83","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/bjh.16103","article-title":"Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab","volume":"186","author":"Sivapalaratnam","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2021.07.009_bib84","first-page":"405","article-title":"Post-transfusion purpura: current perspectives","volume":"10","author":"Hawkins","year":"2019","journal-title":"J\u00a0Blood Med"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3148.1994.tb00236.x","article-title":"Post-transfusion purpura: a survey of 12 Danish cases with special reference to immunoglobulin G subclasses of the platelet antibodies","volume":"4","author":"Taaning","year":"1994","journal-title":"Transfus Med"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib86","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2141.1986.tb02198.x","article-title":"Post-transfusion purpura","volume":"64","author":"Mueller-Eckhardt","year":"1986","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.cll.2021.07.009_bib87","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/trf.14824","article-title":"Posttransfusion purpura with antibodies against human platelet antigen-4a following checkpoint inhibitor therapy: a case report and review of the literature","volume":"58","author":"Vu","year":"2018","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1423-0410.2008.01073.x","article-title":"Transfusion-associated graft-versus-host disease","volume":"95","author":"Dwyre","year":"2008","journal-title":"Vox Sang"},{"issue":"11","key":"10.1016\/j.cll.2021.07.009_bib89","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJM199303183281105","article-title":"Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors","volume":"328","author":"Shivdasani","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM198907063210105","article-title":"The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery","volume":"321","author":"Thaler","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib91","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tmrv.2008.09.006","article-title":"Transfusion-associated graft-versus-host disease","volume":"23","author":"R\u00fchl","year":"2009","journal-title":"Transfus Med Rev"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib92","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1537-2995.2006.00853.x","article-title":"Transfusion-associated graft-versus-host disease: less fresh blood and more gray (Gy) for an aging population","volume":"46","author":"Klein","year":"2006","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.cll.2021.07.009_bib93","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/trf.14589","article-title":"Amotosalen\/UVA treatment inactivates T\u00a0cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease","volume":"58","author":"Castro","year":"2018","journal-title":"Transfusion"},{"issue":"17","key":"10.1016\/j.cll.2021.07.009_bib94","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2018-08-833962","article-title":"Transfusion-related red blood cell alloantibodies: induction and consequences","volume":"133","author":"Tormey","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0973-6247.137433","article-title":"Red cell alloimmunization in transfused patients: a silent epidemic revisited","volume":"8","author":"Pandey","year":"2014","journal-title":"Asian J Transfus Sci"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload","volume":"102","author":"Hoffbrand","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib97","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2257.1985.tb00026.x","article-title":"Transfusional iron overload","volume":"7","author":"Marcus","year":"1985","journal-title":"Clin Lab Haematol"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib98","doi-asserted-by":"crossref","first-page":"e00352","DOI":"10.1128\/JCM.00352-18","article-title":"Transfusion-transmitted infections: an update on product screening, diagnostic techniques, and the path ahead","volume":"56","author":"Dean","year":"2018","journal-title":"J\u00a0Clin Microbiol"},{"issue":"4","key":"10.1016\/j.cll.2021.07.009_bib99","first-page":"419","article-title":"Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis among blood donors in Koudougou (Burkina Faso) in 2009","volume":"9","author":"Nagalo","year":"2011","journal-title":"Blood Transfus"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/labmed\/lmw003","article-title":"Prevalence of transfusion-transmissible infections in donors to an Ethiopian blood bank between 2009 and 2013 and donation factors that Would improve the safety of the blood supply in underdeveloped countries","volume":"47","author":"Birhaneselassie","year":"2016","journal-title":"Lab Med May"},{"key":"10.1016\/j.cll.2021.07.009_bib101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.11604\/pamj.2019.34.31.17885","article-title":"Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya","volume":"34","author":"Bartonjo","year":"2019","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.cll.2021.07.009_bib102","doi-asserted-by":"crossref","DOI":"10.1111\/trf.16005","article-title":"Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: the Transfusion-Transmissible Infections Monitoring System (TTIMS)","author":"Steele","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.009_bib103","series-title":"Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion","year":"2020"},{"issue":"12","key":"10.1016\/j.cll.2021.07.009_bib104","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1111\/trf.14308","article-title":"Apheresis technology correlates with bacterial contamination of platelets and reported septic transfusion reactions","volume":"57","author":"Eder","year":"2017","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib105","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2008-07-077370","article-title":"The hazards of blood transfusion in historical perspective","volume":"112","author":"Alter","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib106","first-page":"30","article-title":"Blood product transfusion in adults: indications, adverse reactions, and modifications","volume":"102","author":"Raval","year":"2020","journal-title":"Am Fam Physician"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tmrv.2020.02.001","article-title":"Screening blood donors for HIV, HCV, and HBV at the American red cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016","volume":"34","author":"Dodd","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.cll.2021.07.009_bib108","series-title":"The standing advisory committee on transfusion transmitted infections (SACTTI). Joint UKBTS Professional advisory committee","year":"2020"},{"issue":"3","key":"10.1016\/j.cll.2021.07.009_bib109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2015.03.001","article-title":"Keeping blood transfusion safe from west nile virus: American Red Cross experience, 2003 to 2012","volume":"29","author":"Dodd","year":"2015","journal-title":"Transfus Med Rev"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/trf.15568","article-title":"Probable transfusion transmission of West Nile virus from an apheresis platelet that screened non-reactive by individual donor-nucleic acid testing","volume":"60","author":"Hayes","year":"2020","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"10.1016\/j.cll.2021.07.009_bib111","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/trf.13478","article-title":"Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis","volume":"56","author":"Mainou","year":"2016","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.cll.2021.07.009_bib114","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/trf.15941","article-title":"Use of a rapid electronic survey methodology to estimate blood donors' potential exposure to emerging infectious diseases: application of a statistically representative sampling methodology to assess risk in US blood centers","volume":"60","author":"Whitaker","year":"2020","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.009_bib115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tmrv.2004.10.001","article-title":"Proceedings of a consensus conference: towards an understanding of TRALI","volume":"19","author":"Goldman","year":"2005","journal-title":"Transfus Med Rev"},{"issue":"12","key":"10.1016\/j.cll.2021.07.009_bib116","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.0041-1132.2004.04347.x","article-title":"Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel","volume":"44","author":"Kleinman","year":"2004","journal-title":"Transfusion"},{"issue":"17","key":"10.1016\/j.cll.2021.07.009_bib117","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cll.2021.07.009_bib118","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1537-2995.2010.02622.x","article-title":"Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing","volume":"50","author":"Zou","year":"2010","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.cll.2021.07.009_bib119","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tmrv.2011.07.007","article-title":"Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations","volume":"26","author":"Zou","year":"2012","journal-title":"Transfus Med Rev"},{"issue":"10","key":"10.1016\/j.cll.2021.07.009_bib120","doi-asserted-by":"crossref","first-page":"e013483","DOI":"10.1136\/bmjopen-2016-013483","article-title":"Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study","volume":"6","author":"Tay","year":"2016","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2021.07.009_bib121","first-page":"1s","article-title":"Emerging infectious disease agents and their potential threat to transfusion safety","volume":"49","author":"Stramer","year":"2009","journal-title":"Transfusion"},{"issue":"10 Pt 2","key":"10.1016\/j.cll.2021.07.009_bib122","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/trf.12371","article-title":"Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress","volume":"53","author":"Stramer","year":"2013","journal-title":"Transfusion"},{"issue":"1647","key":"10.1016\/j.cll.2021.07.009_bib123","first-page":"2111","article-title":"Temporal trends in the discovery of human viruses","volume":"275","author":"Woolhouse","year":"2008","journal-title":"Proc Biol Sci"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:58:11Z","timestamp":1759449491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271221000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0272271221000536"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2021.07.009","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transfusion Reactions and Adverse Events","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2021.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}